Parkinson s Disease-Diagnosis and Clinical Management

Stewart Factor, MD and William Weiner, MD1933864001, 9781933864006, 9781934559871

Parkinson’s disease (PD) is the second most common neurodegenerative disease in the world. Still the only major text on the subject, the completely revised and updated second edition of Parkinson s Disease: Diagnosis and Clinical Management comes at a time when specialists have made important advances in our understanding of the etiology, pathogenesis, investigation, and management of Parkinson s disease.

---

Table of contents :
Cover……Page 1
Title Page……Page 3
Table of Contents……Page 9
Foreword……Page 15
Preface……Page 17
Acknowledgments……Page 21
Contributors……Page 23
1. James Parkinson: The Man and the Essay……Page 33
2. Paralysis Agitans in the Nineteenth Century……Page 45
3. Charcot and Parkinson’s Disease……Page 51
4. Timeline of Parkinson’s Disease History Since 1900……Page 63
5. Epidemiology……Page 69
6. Cardinal Features of Early Parkinson’s Disease……Page 75
7. Gait Disturbances……Page 85
8. Sensory Symptoms……Page 95
9. Voice, Speech, and Swallowing Disorders……Page 107
10. Gastrointestinal Features……Page 129
11. Autonomic Dysfunction……Page 137
12. Sleep Disorders……Page 149
13. Natural History……Page 157
14. Clinical Rating Scales……Page 165
15. Dementia……Page 177
16. Depression……Page 189
17. Anxiety and Panic……Page 209
18. Apathy and Amotivation……Page 219
19. Impulse-control Disorders……Page 231
20. Neuropathology……Page 243
21. Neurochemistry……Page 257
22. Basal Ganglia: Anatomy and Physiology……Page 275
23. Dopamine Receptor Diversity……Page 297
24. Status of Biological Markers……Page 307
25. Positron Emission Tomography……Page 315
26. Single Photon Emission Computed Tomography……Page 323
27. Magnetic Resonance Imaging……Page 335
28. Controversies in Neuroimaging……Page 347
29. Animal Models……Page 359
30. Pathogenesis: Oxidative Stress, Mitochondrial Dysfunction, and Excitotoxicity……Page 371
31. The Concept and Mechanisms of Programmed Cell Death……Page 395
32. Protein Aggregation……Page 411
33. Etiology: The Role of Environment and Genetics……Page 425
34. The Impact of MPTP on Parkinson’s Disease Research: Past, Present, and Future……Page 445
35. Rotenone and Other Toxins……Page 475
36. Inflammation……Page 487
37. Genetics……Page 493
38. Levodopa: A Pharmacologic Miracle Four Decades Later……Page 509
39. Amantadine and Anticholinergics……Page 529
40. Monoamine Oxidase Inhibitors……Page 537
41. Dopamine Agonists……Page 553
42. Catechol-O-Methyltransferase Inhibitors……Page 571
43. Excitatory Amino Acid Antagonists……Page 583
44. Adenosine A2A Receptor Antagonists……Page 595
45. Complementary and Alternative Medicine……Page 601
46. Motor Fluctuations and Dyskinesia……Page 613
47. Fluctuations of Nonmotor Symptoms……Page 623
48. Psychosis and Other Behaviors……Page 631
49. Treatment of Dementia……Page 651
50. Status of Neuroprotective Therapies……Page 657
51. Symptomatic Treatment Approaches for Early Parkinson’s Disease……Page 671
52. Progress in Gene Therapy……Page 681
53. Genetic Testing……Page 693
54. Deep Brain Stimulation……Page 701
55. Neural Transplantation: Yesterday, Today, and Tomorrow……Page 727
56. Stereotactic Pallidotomy and Thalamotomy……Page 737
57. Parkinson’s-plus Disorders……Page 765
58. Symptomatic Parkinsonism……Page 779
59. Outcome Measures……Page 789
60. Family Caregiving……Page 797
61. Economics……Page 809
62. Driving……Page 817
63. The Patient’s Perspective……Page 829
A……Page 837
C……Page 839
D……Page 841
E……Page 844
G……Page 845
H……Page 846
L……Page 847
M……Page 848
N……Page 849
P……Page 851
R……Page 853
S……Page 854
U……Page 856
Z……Page 857